Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers SAN ...

Title: Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures Poster/Abstract: 2949 Session: ...

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase ...

Following the presentation on April 19, 2026 from 2:00–5:00 PM PT, the poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its ...

Under Nasdaq’s listing rules, the Company has 60 calendar days from receipt of the notice to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an ...

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer ...

In preclinical studies, XTX601 demonstrated the potential to achieve a wide therapeutic index. XTX601 demonstrated protease-dependent activation and tumor cell killing in high- and low-expression ...

ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced ...

BD200 demonstrated superior uptake and cellular cytotoxicity when compared to approved drugs targeting either Trop-2 or Nectin-4 – – BD200 showed strong anti-tumor activity across clinically relevant ...

LUND, Sweden, April 17, 2026 (GLOBE NEWSWIRE) -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces that it ...

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at ...

Designed with our AI-Immunology™ platform, EVX-01 and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient's immune system to fight off ...